Diagnosis, treatment, and follow-up of borderline ovarian tumors

Oncologist

Volumn 17, Issue 12, 2012, Pages 1515-1533

  Fischerova, Daniela ^a   Zikan, Michal ^a   Dundr, Pavel ^a   Cibula, David ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Borderline ovarian tumor; Conservative surgery; Fertility; Prognostic parameter; Recurrence; Ultrasound

Indexed keywords

ANASTROZOLE; CA 125 ANTIGEN; CA 19-9 ANTIGEN; LEUPRORELIN; TAMOXIFEN;

ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER STAGING; CELL INVASION; CELL PROLIFERATION; CYSTECTOMY; CYTOGENETICS; DISEASE SEVERITY; ECHOGRAPHY; FEMALE; FERTILIZATION IN VITRO; GENE MUTATION; HISTOLOGY; HUMAN; INCIDENCE; INFERTILITY; LAPAROSCOPY; LAPAROTOMY; MINIMAL RESIDUAL DISEASE; MUTATION; OVARY CANCER; PEROPERATIVE CARE; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL RATE;

CHEMORADIOTHERAPY, ADJUVANT; FEMALE; HUMANS; INFERTILITY; LAPAROSCOPY; LAPAROTOMY; MULTICENTER STUDIES AS TOPIC; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PROGNOSIS; RISK FACTORS;

EID: 84871581544     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0139     Document Type: Article

References (128)

1. Sutton GP. Ovarian tumors of low malignant potential. In: Rubin SC, Sutton GP, eds. Ovarian Cancer, 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2001: 399-417.
2. Katsube Y, Berg JW, Silverberg SG. Epidemiologic pathology of ovarian tumors: A histopathologic review of primary ovarian neoplasms diagnosed in the Denver Standard Metropolitan Statistical Area, 1 July-31 December 1969 and 1 July-31 December 1979. Int J Gynecol Pathol 1982;1:3-16.
3. Skirnisdottir I, Garmo H, Wilander E et al. Borderline ovarian tumors in Sweden 1960-2005: Trends in incidence and age at diagnosis compared to ovarian cancer. Int J Cancer 2008;123:1897-1901.
4. Sherman ME, Berman J, Birrer MJ et al. Current challenges and opportunities for research on borderline ovarian tumors. Hum Pathol 2004;35:961-970.
5. Bjorge T, Engeland A, Hansen S et al. Trends in the incidence of ovarian cancer and borderline tumours in Norway, 1954-1993. Int J Cancer 1997;71:780-786.
6. Heintz AP, Odicino F, Maisonneuve P et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95(suppl 1):S161-S192.
7. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: Collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008;371: 303-314.
8. van Leeuwen FE, Klip H, Mooij TM et al. Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort. Hum Reprod 2011;26:3456-3465.
9. du Bois A, Ewald-Riegler N, du Bois O et al. Borderline tumors of the ovary: A systematic review. Geburtsh Frauenheilk 2009;69:807-833.
10. Sherman ME, Mink PJ, Curtis R et al. Survival among women with borderline ovarian tumors and ovarian carcinoma: A population-based analysis. Cancer 2004;100:1045-1052.
11. Tinelli R, Tinelli A, Tinelli FG et al. Conservative surgery for borderline ovarian tumors: A review. Gynecol Oncol 2006;100:185-191.
12. Trope C, Davidson B, Paulsen T et al. Diagnosis and treatment of borderline ovarian neoplasms "the state of the art. " Eur J Gynaecol Oncol 2009;30:471-482.
13. Beller U, Benedet JL, Creasman WT et al. Carcinoma of the vagina. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95(suppl 1):S29-S42.
14. Morice P. Borderline tumours of the ovary and fertility. Eur J Cancer 2006;42:149-158.
15. Burger CW, Prinssen HM, Baak JP et al. The management of borderline epithelial tumors of the ovary. Int J Gynecol Cancer 2000;10:181-197.
16. Bjorge T, Lie AK, Hovig E et al. BRCA1 mutations in ovarian cancer and borderline tumours in Norway: A nested case-control study. Br J Cancer 2004;91:1829-1834.
17. Gotlieb WH, Chetrit A, Menczer J et al. Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer. Gynecol Oncol 2005;97:780-783.
18. Cibula D, Gompel A, Mueck AO et al. Hormonal contraception and risk of cancer. Hum Reprod Update 2010;16:631-650.
19. Harris R, Whittemore AS, Itnyre J. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136: 1204-1211.
20. Fathalla MF. Incessant ovulation: A factor in ovarian neoplasia? Lancet 1971;2:163.
21. Riman T, Dickman PW, Nilsson S et al. Risk factors for epithelial borderline ovarian tumors: Results of a Swedish case-control study. Gynecol Oncol 2001;83: 575-585.
22. Kumle M, Weiderpass E, Braaten T et al. Risk for invasive and borderline epithelial ovarian neoplasias following use of hormonal contraceptives: The Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Br J Cancer 2004;90:1386-1391.
23. Huusom LD, Frederiksen K, Hogdall EV et al. Association of reproductive factors, oral contraceptive use and selected lifestyle factors with the risk of ovarian borderline tumors: A Danish case-control study. Cancer Causes Control 2006;17:821-829.
24. Ness RB, Cramer DW, Goodman MT et al. Infertility, fertility drugs, and ovarian cancer: A pooled analysis of case-control studies. Am J Epidemiol 2002;155: 217-224.
25. Olsen CM, Green AC, Nagle CM et al. Epithelial ovarian cancer: Testing the "androgens hypothesis. " Endocr Relat Cancer 2008;15:1061-1068.
26. Seidman JD, Cho KR, Ronnett BM et al. Surface epithelial tumors of the ovary. In: Kurman RJ, Ellenson LH, Ronnett BM, eds. Blaustein_s Pathology of the Female Genital Tract, 6th ed. New York: Springer Science_ Business Medica, 2011:680-772.
27. Widschwendter M, Fiegl H, Egle D et al. Epigenetic stem cell signature in cancer. Nat Genet 2007;39: 157-158.
28. Fiegl H, Windbichler G, Mueller-Holzner E et al. HOXA11 DNA methylation: A novel prognostic biomarker in ovarian cancer. Int J Cancer 2008;123:725-729.
29. Bell DA. Origins and molecular pathology of ovarian cancer. Mod Pathol 2005;18(suppl 2):S19-S32.
30. Shih Ie M, Kurman RJ. Molecular pathogenesis of ovarian borderline tumors: New insights and old challenges. Clin Cancer Res 2005;11:7273-7279.
31. Shih Ie M, Kurman RJ. Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004;164:1511-1518.
32. Lee KR, Tavassoli FA, Prat J et al. Tumours of the ovary and peritoneum. In Tavassoli FA, Devilee P, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press, 2003:113-202.
33. Seidman JD, Kurman RJ. Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol 1996;20:1331-1345.
34. Seidman JD, Kurman RJ. Ovarian serous borderline tumors: A critical review of the literature with emphasis on prognostic indicators. Hum Pathol 2000;31: 539-557.
35. Seidman JD, Khedmati F, Yemelyanova AV. Ovarial low grade serous neoplasm: Evaluation of sampling recommendations based on tumors expected to have invasion (those with peritoneal invasive low grade serous carcinoma (invasive implants). Mod Pathol 2009;22(suppl 1):Abstract 236A.
36. Seidman JD, Soslow RA, Vang R et al. Borderline ovarian tumors: Diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images. Hum Pathol 2004;35:918-933.
37. McKenney JK, Balzer BL, Longacre TA. Lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors): Pathology, prognosis, and proposed classification. Am J Surg Pathol 2006;30:614-624.
38. Chang SJ, Ryu HS, ChangKHet al. Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumors. Acta Obstet Gynecol Scand 2008;87:476-481.
39. Cuatrecasas M, Villanueva A, Matias-Guiu X et al. K-ras mutations in mucinous ovarian tumors: A clinicopathologic and molecular study of 95 cases. Cancer 1997;79:1581-1586.
40. Shappell HW, Riopel MA, Smith Sehdev AE et al. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: Atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas. Am J Surg Pathol 2002;26:1529-1541.
41. Meriden Z, Yemelyanova AV, Vang R et al. Ovarian metastases of pancreaticobiliary tract adenocarcinomas: Analysis of 35 cases, with emphasis on the ability of metastases to simulate primary ovarian mucinous tumors. Am J Surg Pathol 2011;35:276-288.
42. Ronnett BM, Kajdacsy-Balla A, Gilks CB et al. Mucinous borderline ovarian tumors: Points of general agreement and persistent controversies regarding nomenclature, diagnostic criteria, and behavior. Hum Pathol 2004;35:949-960.
43. McKenney JK, Soslow RA, Longacre TA. Ovarian mature teratomas with mucinous epithelial neoplasms: Morphologic heterogeneity and association with pseudomyxoma peritonei. Am J Surg Pathol 2008;32:645-655.
44. Ronnett BM, Seidman JD. Mucinous tumors arising in ovarian mature cystic teratomas: Relationship to the clinical syndrome of pseudomyxoma peritonei. Am J Surg Pathol 2003;27:650-657.
45. Abu-Rustum NR, Ramirez PT. Surgical postgraduate courses. Gynecologic oncology. Gynecol Oncol 2007;104(2 suppl 1):1.
46. Gershenson DM, Silva EG, Levy L et al. Ovarian serous borderline tumors with invasive peritoneal implants. Cancer 1998;82:1096-1103.
47. Gershenson DM, Sun CC, Lu KH et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol 2006;108:361-368.
48. Gershenson DM, Silva EG, Tortolero-Luna G et al. Serous borderline tumors of the ovary with noninvasive peritoneal implants. Cancer 1998;83:2157-2163.
49. Kane A, Uzan C, Rey A et al. Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants. Oncologist 2009;14:591-600.
50. Seidman AJ, Varallo MR. Micropapillary serous carcinoma: The solution to the ovarian borderline tumor conundrum. Pathol Case Rev 2007;12:136-142.
51. Prat J, De Nictolis M. Serous borderline tumors of the ovary: A long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. Am J Surg Pathol 2002;26:1111-1128.
52. McKenney JK, Balzer BL, Longacre TA. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): A reevaluation of the concept of stromal microinvasion. Am J Surg Pathol 2006;30:1209-1221.
53. Dube V, Roy M, Plante M et al. Mucinous ovarian tumors of Mullerian-type: An analysis of 17 cases including borderline tumors and intraepithelial, microinvasive, and invasive carcinomas. Int J Gynecol Pathol 2005;24:138-146.
54. Rodriguez IM, Irving JA, Prat J. Endocervical-like mucinous borderline tumors of the ovary: A clinicopathologic analysis of 31 cases. Am J Surg Pathol 2004;28: 1311-1318.
55. Kaern J, Trope C, Kjorstad KE et al. Cellular DNA content as a new prognostic tool in patients with borderline tumors of the ovary. Gynecol Oncol 1990;38:452-457.
56. Meyer JS, Gersell DJ, Yim S. Cell proliferation in ovarian carcinoma: Superior accuracy of S-phase fraction (SPF) by DNA labeling index versus flow cytometric SPF, lack of independent prognostic power for SPF and DNA ploidy, and limited effect of SPF on tumor growth rate. Gynecol Oncol 2001;81:466-476.
57. Verbruggen MB, van Diest PJ, Baak JP et al. The prognostic and clinical value of morphometry and DNA cytometry in borderline ovarian tumors: A prospective study. Int J Gynecol Pathol 2009;28:35-40.
58. Menczer J, Chetrit A, Sadetzki S. The effect of hysterectomy on survival of patients with borderline ovarian tumors. Gynecol Oncol 2012;125:372-375.
59. Ramirez PT, Milam MR. Laparoscopic extraperitoneal paraaortic lymphadenectomy in patients with locally advanced cervical cancer. Gynecol Oncol 2007; 104(2 suppl 1):9-12.
60. Bristow RE, Gossett DR, Shook DR et al. Micropapillary serous ovarian carcinoma: Surgical management and clinical outcome. Gynecol Oncol 2002;86: 163-170.
61. Fauvet R, Boccara J, Dufournet C et al. Restaging surgery for women with borderline ovarian tumors: Results of a French multicenter study. Cancer 2004;100: 1145-1151.
62. Zapardiel I, Rosenberg P, Peiretti M et al. The role of restaging borderline ovarian tumors: Single institution experience and review of the literature. Gynecol Oncol 2010;119:274-277.
63. Winter WE 3rd, Kucera PR, RodgersWet al. Surgical staging in patients with ovarian tumors of low malignant potential. Obstet Gynecol 2002;100:671-676.
64. Slomovitz BM, Sun CC, Frumovitz M et al. Are women ready for the HPV vaccine? Gynecol Oncol 2006;103:151-154.
65. Ramirez PT, Slomovitz BM, McQuinn L et al. Role of appendectomy at the time of primary surgery in patients with early-stage ovarian cancer. Gynecol Oncol 2006;103:888-890.
66. Koskas M, Uzan C, Gouy S et al. Prognostic factors of a large retrospective series of mucinous borderline tumors of the ovary (excluding peritoneal pseudomyxoma). Ann Surg Oncol 2011;18:40-48.
67. Slomovitz BM, Ramirez PT, Frumovitz M et al. Electrothermal bipolar coagulation for pelvic exenterations. Gynecol Oncol 2006;102:534-536.
68. Ramirez PT, Slomovitz BM, Soliman PT et al. Total laparoscopic radical hysterectomy and lymphadenectomy: the MD Anderson Cancer Center experience. Gynecol Oncol 2006;102:252-255.
69. Suh-Burgmann E. Long-term outcomes following conservative surgery for borderline tumor of the ovary: A large population-based study. Gynecol Oncol 2006; 103:841-847.
70. Zanetta G, Rota S, Chiari S et al. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: A prospective study. J Clin Oncol 2001;19:2658-2664.
71. Kurman RJ, Trimble CL. The behavior of serous tumors of low malignant potential: Are they ever malignant? Int J Gynecol Pathol 1993;12:120-127.
72. Morice P, Camatte S, Rey A et al. Prognostic factors for patients with advanced stage serous borderline tumours of the ovary. Ann Oncol 2003;14:592-598.
73. Camatte S, Morice P, Pautier P et al. Fertility results after conservative treatment of advanced stage serous borderline tumour of the ovary. BJOG 2002;109: 376-380.
74. De Iaco P, Ferrero A, Rosati F et al. Behaviour of ovarian tumors of low malignant potential treated with conservative surgery. Eur J Surg Oncol 2009;35:643-648.
75. Fauvet R, Boccara J, Dufournet C et al. Laparoscopic management of borderline ovarian tumors: Results of a French multicenter study. Ann Oncol 2005;16: 403-410.
76. Trope C, Kaern J, Vergote IB et al. Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors. Gynecol Oncol 1993;51:236-243.
77. Valentin L. Prospective cross-validation of Doppler ultrasound examination and gray-scale ultrasound imaging for discrimination of benign and malignant pelvic masses. Ultrasound Obstet Gynecol 1999;14:273-283.
78. Valentin L, Hagen B, Tingulstad S et al. Comparison of "pattern recognition" and logistic regression models for discrimination between benign and malignant pelvic masses: A prospective cross validation. Ultrasound Obstet Gynecol 2001;18:357-365.
79. Timmerman D, Schwarzler P, Collins WP et al. Subjective assessment of adnexal masses with the use of ultrasonography: An analysis of interobserver variability and experience. Ultrasound Obstet Gynecol 1999;13: 11-16.
80. Valentin L, Ameye L, Jurkovic D et al. Which extrauterine pelvic masses are difficult to correctly classify as benign or malignant on the basis of ultrasound findings and is there a way of making a correct diagnosis? Ultrasound Obstet Gynecol 2006;27:438-444.
81. Valentin L, Ameye L, Testa A et al. Ultrasound characteristics of different types of adnexal malignancies. Gynecol Oncol 2006;102:41-48.
82. Yazbek J, Ameye L, Timmerman D et al. Use of ultrasound pattern recognition by expert operators to identify borderline ovarian tumors:Astudy of diagnostic performance and interobserver agreement. Ultrasound Obstet Gynecol 2010;35:84-88.
83. Fruscella E, Testa AC, Ferrandina G et al. Ultrasound features of different histopathological subtypes of borderline ovarian tumors. Ultrasound Obstet Gynecol 2005;26:644-650.
84. Yazbek J, Raju KS, Ben-Nagi J et al. Accuracy of ultrasound subjective "pattern recognition" for the diagnosis of borderline ovarian tumors. Ultrasound Obstet Gynecol 2007;29:489-495.
85. Exacoustos C, Romanini ME, Rinaldo D et al. Preoperative sonographic features of borderline ovarian tumors. Ultrasound Obstet Gynecol 2005;25:50-59.
86. Pascual MA, Tresserra F, Grases PJ et al. Borderline cystic tumors of the ovary: gray-scale and color Doppler sonographic findings. J Clin Ultrasound 2002; 30:76-82.
87. Sokalska A, Timmerman D, Testa AC et al. Diagnostic accuracy of transvaginal ultrasound examination for assigning a specific diagnosis to adnexal masses. Ultrasound Obstet Gynecol 2009;34:462-470.
88. Valentin L. Use of morphology to characterize and manage common adnexal masses. Best Pract Res Clin Obstet Gynaecol 2004;18:71-89.
89. Van Holsbeke C, Van Calster B, Guerriero S et al. Endometriomas: Their ultrasound characteristics. Ultrasound Obstet Gynecol 2010;35:730-740.
90. Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory. Am J Surg Pathol 2010;34:433-443.
91. Valentin L. Pattern recognition of pelvic masses by gray-scale ultrasound imaging: The contribution of Doppler ultrasound. Ultrasound Obstet Gynecol 1999; 14:338-347.
92. Fischerova D, Franchi D, Testa A et al. Ultrasound in diagnosis of new and borderline ovarian tumors. Ultrasound Obstet Gynecol 2010;36(suppl. 1):Abstract OC01.03.
93. Testa AC, Timmerman D, Exacoustos C et al. The role of CnTI-SonoVue in the diagnosis of ovarian masses with papillary projections: A preliminary study. Ultrasound Obstet Gynecol 2007;29:512-516.
94. Testa AC, Timmerman D, Van Belle V et al. Intravenous contrast ultrasound examination using contrasttuned imaging (CnTI) and the contrast medium SonoVue for discrimination between benign and malignant adnexal masses with solid components. Ultrasound Obstet Gynecol 2009;34:699-710.
95. Alcazar JL, Jurado M. Three-dimensional ultrasound for assessing women with gynecological cancer: A systematic review. Gynecol Oncol 2011;120:340-346.
96. Testa AC, Ludovisi M, Mascilini F et al. Ultrasound evaluation of intra-abdominal sites of disease to predict likelihood of suboptimal cytoreduction in advanced ovarian cancer: A prospective study. Ultrasound Obstet Gynecol 2012;39:99-105.
97. Fischerova D. Ultrasound scanning of the pelvis and abdomen for staging of gynecological tumors: A review. Ultrasound Obstet Gynecol 2011;38:246-266.
98. Shaaban A, Rezvani M. Ovarian cancer: Detection and radiologic staging. Clin Obstet Gynecol 2009;52: 73-93.
99. Valentin L. Imaging in gynecology. Best Pract Res Clin Obstet Gynaecol 2006;20:881-906.
100. deSouza NM, O'Neill R, McIndoe GA et al. Borderline tumors of the ovary: CT and MRI features and tumor markers in differentiation from stage I disease. AJR Am J Roentgenol 2005;184:999-1003.
101. Risum S, Hogdall C, Loft A et al. The diagnostic value of PET/CT for primary ovarian cancer: A prospective study. Gynecol Oncol 2007;105:145-149.
102. Jung DC, Choi HJ, Ju W et al. Discordant MRI/ FDG-PET imaging for the diagnosis of borderline ovarian tumors. Int J Gynecol Cancer 2008;18:637-641.
103. Redman C, Duffy S, Bromham N et al. Recognition and initial management of ovarian cancer: summary of NICE guidance. BMJ 2011;342:d2073.
104. Van Gorp T, Veldman J, Van Calster B et al. Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses. Eur J Cancer 2012;48:1649-1656.
105. Jacobs I, Oram D, Fairbanks J et al. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990;97: 922-929.
106. Van Holsbeke C, Van Calster B, Bourne T et al. External validation of diagnostic models to estimate the risk of malignancy in adnexal masses. Clin Cancer Res 2012;18:815-825.
107. Valentin L, Ameye L, Savelli L et al. Adnexal masses difficult to classify as benign or malignant using subjective assessment of gray-scale and Doppler ultrasound findings: logistic regression models do not help. Ultrasound Obstet Gynecol 2011;38:456-465.
108. Timmerman D, Ameye L, Fischerova D et al. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: Prospective validation by IOTA group. BMJ 2010;341: c6839.
109. Trope CG, Kristensen G, Makar A. Surgery for borderline tumor of the ovary. Semin Surg Oncol 2000; 19:69-75.
110. Uzan C, Kane A, Rey A et al. Outcomes after conservative treatment of advanced-stage serous borderline tumors of the ovary. Ann Oncol 2010;21:55-60.
111. Trillsch F, Mahner S, Ruetzel J et al. Clinical management of borderline ovarian tumors. Expert Rev Anticancer Ther 2010;10:1115-1124.
112. Franchi D, Boveri S, Fruscio R et al. Imaging in gynecological disease: Ultrasound characteristics of ovarian borderline tumor recurrence. Ultrasound Obstet Gynecol 2012 August 1 [Epub ahead of print], doi: 10.1002/uog.12276.
113. Lim-Tan SK, Cajigas HE, Scully RE. Ovarian cystectomy for serous borderline tumors: A follow-up study of 35 cases. Obstet Gynecol 1988;72:775-781.
114. Poncelet C, Fauvet R, Boccara J et al. Recurrence after cystectomy for borderline ovarian tumors: Results of a French multicenter study. Ann Surg Oncol 2006;13: 565-571.
115. Tempfer CB, Polterauer S, Bentz EK et al. Accuracy of intraoperative frozen section analysis in borderline tumors of the ovary: A retrospective analysis of 96 cases and review of the literature. Gynecol Oncol 2007; 107:248-252.
116. Romagnolo C, Gadducci A, Sartori E et al. Management of borderline ovarian tumors: Results of an Italian multicenter study. Gynecol Oncol 2006;101:255-260.
117. Deffieux X, Morice P, Camatte S et al. Results after laparoscopic management of serous borderline tumor of the ovary with peritoneal implants. Gynecol Oncol 2005;97:84-89.
118. Abu-Jawdeh GM, Jacobs TW, Niloff J et al. Estrogen receptor expression is a common feature of ovarian borderline tumors. Gynecol Oncol 1996;60(2):301-307.
119. Lee EJ, Deavers MT, Hughes JI et al. Metastasis to sigmoid colon mucosa and submucosa from serous borderline ovarian tumor: Response to hormone therapy. Int J Gynecol Cancer 2006;16(suppl 1):295-299.
120. Hua K, Feng W, Cao Q et al. Estrogen and progestin regulate metastasis through the PI3K/AKT pathway in human ovarian cancer. Int J Oncol 2008;33:959-967.
121. Fauvet R, Poncelet C, Boccara J et al. Fertility after conservative treatment for borderline ovarian tumors: A French multicenter study. Fertil Steril 2005;83:284-290.
122. Jeruss JS, Woodruff TK. Preservation of fertility in patients with cancer. N Engl J Med 2009;360:902-911.
123. Crispens MA, Bodurka D, Deavers M et al. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol 2002;99:3-10.
124. Bostwick DG, Tazelaar HD, Ballon SC et al. Ovarian epithelial tumors of borderline malignancy. A clinical and pathologic study of 109 cases. Cancer 1986; 58:2052-2065.
125. Silva EG, Gershenson DM, Malpica A et al. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent. Am J Surg Pathol 2006;30:1367-1371.
126. Benedet JL, Bender H, Jones H, 3rd et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000;70:209-262.
127. Zanetta G, Rota S, Lissoni A et al. Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors. Gynecol Oncol 2001; 81:63-66.
128. Papadimitriou DS, Martin-Hirsch P, Kitchener HC et al. Recurrent borderline ovarian tumours after conservative management in women wishing to retain their fertility. Eur J Gynaecol Oncol 1999;20:94-97.